| Pharmaceutical Information |
| Drug Name |
Physostigmine |
| Drug ID |
BADD_D01768 |
| Description |
A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. |
| Indications and Usage |
For the treatment of glaucoma, and in the treatment of severe anticholinergic toxicity. |
| Marketing Status |
Not Available |
| ATC Code |
S01EB05; V03AB19 |
| DrugBank ID |
DB00981
|
| KEGG ID |
D00196
|
| MeSH ID |
D010830
|
| PubChem ID |
5983
|
| TTD Drug ID |
D09JVV
|
| NDC Product Code |
Not Available |
| Synonyms |
Physostigmine | Eserine |
|
| Chemical Information |
| Molecular Formula |
C15H21N3O2 |
| CAS Registry Number |
57-47-6 |
| SMILES |
CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC)C)C |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
|
|
| ADRs Induced by Drug |
|
|
